Sickle Cell Disease After Casgevy: Seven Companies to Watch in 2026

Why It Matters

These emerging modalities could dramatically cut costs and infrastructure needs, expanding curative or disease‑modifying therapy to millions of sickle‑cell patients who currently lack access.

Key Takeaways

• Beam uses base editing to raise fetal hemoglobin above 60%
• Ensoma pursues in vivo HSC editing via viral vectors, avoiding cell collection
• Orna partners with Vertex to deliver gene edits using lipid‑nanoparticle technology
• Agios aims for accelerated approval of oral mitapivat to boost red‑cell energy
• Safi develops 10‑liter manufactured red blood cells for chronic transfusion needs

Pulse Analysis

Casgevy’s approval marked a watershed moment for sickle cell disease, confirming that CRISPR‑based gene editing can correct the underlying mutation. Yet the therapy’s $2.2 million price tag, reliance on autologous stem‑cell harvest, myeloablative conditioning, and a handful of specialized centers have sparked a race to democratize curative treatment. Investors and patients alike are watching how the next generation of companies will address these logistical and financial hurdles while preserving or improving efficacy.

The most immediate evolution is seen in the gene‑editing toolbox itself. Beam Therapeutics leverages base‑editing technology to introduce single‑letter DNA changes that mimic natural fetal‑hemoglobin‑preserving mutations, achieving HbF levels above 60% in early trials. Simultaneously, in‑vivo strategies aim to eliminate the ex vivo step altogether. Boston‑based Ensoma uses viral vectors to edit circulating hematopoietic stem cells, and Orna Therapeutics, in a three‑year partnership with Vertex, applies lipid‑nanoparticle delivery of circular RNA to reach the same target cells. If successful, these platforms could turn a one‑time, hospital‑bound procedure into an outpatient infusion, slashing both cost and complexity.

Beyond gene editing, the pipeline now includes metabolic and transfusion‑focused solutions that may reach patients faster and at lower cost. Agios’s oral pyruvate‑kinase activator mitapivat, slated for an accelerated U.S. review in 2026, improves red‑cell energy metabolism, while Fulcrum’s pociredir raises fetal hemoglobin through epigenetic modulation. On the transfusion side, Safi’s 10‑liter manufactured red blood‑cell system and Scarlet’s engineered red‑cell carriers (backed by £2.6 million, ≈ $3.3 million, funding) aim to alleviate chronic‑transfusion shortages and alloimmunization risks. Together, these diverse approaches promise a multi‑modality future where curative, disease‑modifying, and supportive therapies coexist, expanding access and reshaping the commercial landscape for sickle cell disease.